Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

17Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

We recently showed that the outcome of multiple myeloma (MM) patients treated in the REPEAT study (evaluation of lenalidomide combined with low-dose cyclophosphamide and prednisone (REP) in lenalidomide-refractory MM) was markedly better than what has been described with cyclophosphamide-prednisone alone. The outcome with REP was not associated with plasma cell Cereblon expression levels, suggesting that the effect of REP treatment may involve mechanisms independent of plasma cell Cereblon-mediated direct anti-tumor activity. We therefore hypothesized that immunomodulatory effects contribute to the anti-MM activity of REP treatment, rather than plasma cell Cereblon-mediated effects. Consequently, we now characterized the effect of REP treatment on immune cell subsets in peripheral blood samples collected on day 1 and 14 of cycle 1, as well as on day 1 of cycle 2. We observed a significant mid-cycle decrease in the Cereblon substrate proteins Ikaros and Aiolos in diverse lymphocyte subsets, which was paralleled by an increase in T-cell activation. These effects were restored to baseline at day one of the second cycle, one week after lenalidomide interruption. In vitro, lenalidomide enhanced peripheral blood mononuclear cell-mediated killing of both lenalidomide-sensitive and lenalidomide-resistant MM cells in a co-culture system. These results indicate that the Cereblon-mediated immunomodulatory properties of lenalidomide are maintained in lenalidomide-refractory MM patients and may contribute to immune-mediated killing of MM cells. Therefore, combining lenalidomide with other drugs can have potent effects through immunomodulation, even in patients considered to be lenalidomide-refractory.

References Powered by Scopus

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

2207Citations
N/AReaders
Get full text

Identification of a primary target of thalidomide teratogenicity

1624Citations
N/AReaders
Get full text

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

1391Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

112Citations
N/AReaders
Get full text

Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma

58Citations
N/AReaders
Get full text

The Nitrogen Mustards

36Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Franssen, L. E., Nijhof, I. S., Bjorklund, C. C., Chiu, H., Doorn, R., Van Velzen, J., … Van De Donk, N. W. C. J. (2018). Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. Oncotarget, 9(74), 34009–34021. https://doi.org/10.18632/oncotarget.26131

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 7

70%

Researcher 2

20%

Lecturer / Post doc 1

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

70%

Decision Sciences 1

10%

Pharmacology, Toxicology and Pharmaceut... 1

10%

Neuroscience 1

10%

Save time finding and organizing research with Mendeley

Sign up for free